共 347 条
[71]
Niemeier HM(2016)Glycemic control and weight outcomes for Exenatide once weekly versus Liraglutide in patients with type 2 diabetes: a 1-year retrospective cohort analysis Clin Ther 38 2642-415
[72]
Glass LM(2013)Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program Aliment Pharmacol Ther 37 234-1346
[73]
Dickson RC(2017)Effect of Liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study J Clin Endocrinol Metab 102 407-2593
[74]
Anderson JC(2015)Effects of insulin glargine and Liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial Diabetes Care 38 1339-408
[75]
Vilar-Gomez E(2016)Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial Diabetologia 59 2588-2315
[76]
Martinez-Perez Y(2016)Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis J Hepatol 64 399-529
[77]
Calzadilla-Bertot L(2011)Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes Obesity (Silver Spring) 19 2310-891
[78]
Houghton D(2014)Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes Diabetes Metab Res Rev 30 521-2709
[79]
Thoma C(2016)Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy Diabetes Obes Metab 18 882-1211
[80]
Hallsworth K(2010)Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series Am J Gastroenterol 105 2707-242